首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   59133篇
  免费   5608篇
  国内免费   125篇
耳鼻咽喉   498篇
儿科学   1823篇
妇产科学   1416篇
基础医学   7660篇
口腔科学   1182篇
临床医学   6689篇
内科学   11592篇
皮肤病学   936篇
神经病学   5407篇
特种医学   2149篇
外国民族医学   5篇
外科学   8278篇
综合类   1314篇
一般理论   68篇
预防医学   6344篇
眼科学   1535篇
药学   4202篇
中国医学   79篇
肿瘤学   3689篇
  2022年   470篇
  2021年   1044篇
  2020年   588篇
  2019年   989篇
  2018年   1058篇
  2017年   806篇
  2016年   847篇
  2015年   991篇
  2014年   1370篇
  2013年   2087篇
  2012年   3030篇
  2011年   2977篇
  2010年   1748篇
  2009年   1561篇
  2008年   2718篇
  2007年   2920篇
  2006年   2934篇
  2005年   2861篇
  2004年   2749篇
  2003年   2582篇
  2002年   2466篇
  2001年   1570篇
  2000年   1538篇
  1999年   1396篇
  1998年   715篇
  1997年   626篇
  1996年   614篇
  1995年   508篇
  1994年   512篇
  1993年   494篇
  1992年   1081篇
  1991年   1007篇
  1990年   1034篇
  1989年   870篇
  1988年   917篇
  1987年   863篇
  1986年   802篇
  1985年   861篇
  1984年   754篇
  1983年   635篇
  1982年   490篇
  1981年   489篇
  1980年   472篇
  1979年   674篇
  1978年   513篇
  1977年   393篇
  1976年   414篇
  1974年   441篇
  1973年   393篇
  1972年   389篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Erosive pustular dermatosis of the scalp (EPDS) is an uncommon chronic inflammatory response to scalp trauma that usually resolves with cicatricial alopecia. It most commonly affects elderly patients with a history of actinic damage. Herein, we describe a 16‐year‐old girl with acrofacial dysostosis type 1 presenting after surgery with crusting purulent scalp lesions, whose clinical presentation and histopathologic findings were consistent with EPDS. A review of the literature on EPDS in children is also detailed.  相似文献   
4.
5.
6.
7.
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma  相似文献   
8.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases.  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号